BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 30009773)

  • 1. Immunohistochemistry is a feasible method to screen BRAF V600E mutation in colorectal and papillary thyroid carcinoma.
    Zhang X; Wang L; Wang J; Zhao H; Wu J; Liu S; Zhang L; Li Y; Xing X
    Exp Mol Pathol; 2018 Aug; 105(1):153-159. PubMed ID: 30009773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.
    Zhu X; Luo Y; Bai Q; Lu Y; Lu Y; Wu L; Zhou X
    Exp Mol Pathol; 2016 Feb; 100(1):236-41. PubMed ID: 26795218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing.
    Estrella JS; Tetzlaff MT; Bassett RL; Patel KP; Williams MD; Curry JL; Rashid A; Hamilton SR; Broaddus RR
    Mol Cancer Ther; 2015 Dec; 14(12):2887-95. PubMed ID: 26438153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of BRAF V600E detection approaches in papillary thyroid carcinoma.
    Chen D; Qi W; Zhang P; Zhang Y; Liu Y; Guan H; Wang L
    Pathol Res Pract; 2018 Feb; 214(2):303-307. PubMed ID: 29254799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma.
    Zagzag J; Pollack A; Dultz L; Dhar S; Ogilvie JB; Heller KS; Deng FM; Patel KN
    Surgery; 2013 Dec; 154(6):1199-204; discussion 1204-5. PubMed ID: 23931769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma.
    Zimmermann AK; Camenisch U; Rechsteiner MP; Bode-Lesniewska B; Rössle M
    Cancer Cytopathol; 2014 Jan; 122(1):48-58. PubMed ID: 24039206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma.
    Sun J; Zhang J; Lu J; Gao J; Lu T; Ren X; Duan H; Liang Z
    Int J Clin Exp Pathol; 2015; 8(11):15072-8. PubMed ID: 26823846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Immunohistochemistry and Direct Sequencing Methods for Identification of the BRAF
    Kim JK; Seong CY; Bae IE; Yi JW; Yu HW; Kim SJ; Won JK; Chai YJ; Choi JY; Lee KE
    Ann Surg Oncol; 2018 Jun; 25(6):1775-1781. PubMed ID: 29611028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF Immunohistochemistry Using Clone VE1 is Strongly Concordant with BRAF(V600E) Mutation Test in Papillary Thyroid Carcinoma.
    Pyo JS; Sohn JH; Kang G
    Endocr Pathol; 2015 Sep; 26(3):211-7. PubMed ID: 25957797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma.
    Dvorak K; Aggeler B; Palting J; McKelvie P; Ruszkiewicz A; Waring P
    Pathology; 2014 Oct; 46(6):509-17. PubMed ID: 25014730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays.
    Ilie MI; Lassalle S; Long-Mira E; Bonnetaud C; Bordone O; Lespinet V; Lamy A; Sabourin JC; Haudebourg J; Butori C; Guevara N; Peyrottes I; Sadoul JL; Bozec A; Santini J; Capper D; von Deimling A; Emile JF; Hofman V; Hofman P
    Thyroid; 2014 May; 24(5):858-66. PubMed ID: 24417277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A testing algorithm for detection of the B-type Raf kinase V600E mutation in papillary thyroid carcinoma.
    Kim YH; Choi SE; Yoon SO; Hong SW
    Hum Pathol; 2014 Jul; 45(7):1483-8. PubMed ID: 24745617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VE1 immunohistochemistry is an adjunct tool for detection of BRAF
    Rashid FA; Tabassum S; Khan MS; Ansari HR; Asif M; Sheikh AK; Sameer Aga S
    J Clin Lab Anal; 2021 Feb; 35(2):e23628. PubMed ID: 33305405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Molecular Methods and BRAF Immunohistochemistry (VE1 Clone) for the Detection of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis.
    Parker KG; White MG; Cipriani NA
    Head Neck Pathol; 2020 Dec; 14(4):1067-1079. PubMed ID: 32358715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers.
    Crescenzi A; Guidobaldi L; Nasrollah N; Taccogna S; Cicciarella Modica DD; Turrini L; Nigri G; Romanelli F; Valabrega S; Giovanella L; Onetti Muda A; Trimboli P
    Horm Metab Res; 2014 May; 46(5):370-4. PubMed ID: 24570209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma.
    Bullock M; O'Neill C; Chou A; Clarkson A; Dodds T; Toon C; Sywak M; Sidhu SB; Delbridge LW; Robinson BG; Learoyd DL; Capper D; von Deimling A; Clifton-Bligh RJ; Gill AJ
    Endocr Relat Cancer; 2012 Dec; 19(6):779-84. PubMed ID: 22997209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemistry as an accurate tool for evaluating BRAF-V600E mutation in 130 samples of papillary thyroid cancer.
    Abd Elmageed ZY; Sholl AB; Tsumagari K; Al-Qurayshi Z; Basolo F; Moroz K; Boulares AH; Friedlander P; Miccoli P; Kandil E
    Surgery; 2017 Apr; 161(4):1122-1128. PubMed ID: 27919446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma.
    Rössle M; Sigg M; Rüschoff JH; Wild PJ; Moch H; Weber A; Rechsteiner MP
    Virchows Arch; 2013 Nov; 463(5):623-31. PubMed ID: 24085553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma.
    Jung YY; Yoo JH; Park ES; Kim MK; Lee TJ; Cho BY; Chung YJ; Kang KH; Ahn HY; Kim HS
    Pathol Res Pract; 2015 Feb; 211(2):162-70. PubMed ID: 25468810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical detection of the BRAF V600E mutation in papillary thyroid carcinoma. Evaluation against real-time polymerase chain reaction.
    Paja Fano M; Ugalde Olano A; Fuertes Thomas E; Oleaga Alday A
    Endocrinol Diabetes Nutr; 2017 Feb; 64(2):75-81. PubMed ID: 28440781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.